Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of the myeloid stem cell. They are generally a disease of the elderly and they are clinically characterized by cytopenias, including thrombocytopenia [1]. A large retrospective study of patients with MDS found bleeding to be the cause of death of around 10% of patients with MDS and to increase notably when platelet count was lower than 20  × 109/L [2].

Source: Leukemia Research - August 31, 2018 Category: Hematology Authors: Marc Sorigue, Javier Nieto, Mireia Santos-Gomez, Edurne Sarrate, Maria-Jos é Jiménez, Cristian Morales-Indiano, Laia Lopez-Viaplana, Elisa Orna, Jose-Tomas Navarro, Josep-Maria Ribera, Blanca Xicoy Tags: Research paper Source Type: research